I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA

79

DAFTAR PUSTAKA

Aboudara, M. C. et al. 2008. Hyperkalemia After Packed Red Blood Cell

Transfusion in Trauma Patients. The Journal of Trauma: Injury,
Infection, and Critical Care, 64(Supplement), pp. S86–S91.
Agarwal, A. and Nath, K. A. 2015. Pathophysiology of Progression: Organ
and Cellular Considerations. In: Kimmel, P. L. and Rosenberg, M.
(Eds.). Chronic Renal Disease. 1st edn. Waltham: Elsevier, p. 137.
Allon, M. and Copkney, C. 1990. Albuterol and Insulin for The Treatment
of Hyperkalemia in Hemodialysis Patient. Kidney International. 38,
pp. 869–872.
American Heart Association (AHA). 2005. Part 10.1: Life-threatening
electrolyte abnormalities.Circulation, 112(24 SUPPL.), pp. 121–
125.
Bandak, G. et al. 2017. Hyperkalemia after initiating renin-angiotensin
system blockade: The Stockholm Creatinine Measurements
(SCREAM) project’, Journal of the American Heart Association,
6(7).
Betts, K. et al. 2018. The Prevalence Of Hyperkalemia In The United
States, Current Medical Research And Opinion, 34(6), pp. 971–
978.
Bomback, A. S. et al, 2010. Sugar-sweetened soda consumption,
hyperuricemia, and kidney disease. Kidney International, 77(7), pp.
609–616.
Brayfield, A. Ed. 2014. Martindale: The Complete Drug Reference. 38th
edn. London: Pharmaceutical Press, p.1387; 1575.
Bratusch-Marrain, P. et al. 1985. Acetyl-salicylic acid impairs insulin-
mediated glucose utilization and reduces insulin clearance in healthy
and non-insulin-dependent diabetic man. Diabetes, 28(9), pp. 671–
676.
Brophy, D. F. 2014. Disorders of Potassium and Magnesium
Homeostasis.In: Dipiro,Joseph T.;Talbert,Robert L.;Yee,Gary
C.;Matzke,Gary R.;Wells,Barbara G.;Posey, L. M. (Eds.).
Pharmacotheraphy: A Pathophysiologic Approach. 9th edn. New
York: McGraw-Hill Education, pp. 790–800.
Campese, V. M. and Adenuga, G. 2016. Electrophysiological and clinical

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
80

consequences of hyperkalemia. Kidney International Supplements,

6(1), pp. 16–19.
Chaitman, M., Dixit, D. and Bridgeman, M. B. 2016. Potassium-Binding
Agents for the Clinical Management of Hyperkalemia. Pharmacy
and Therapeutics, 41(1), pp. 43–50.
Chen, M. and Robertson, R. P. 1978. Restoration of the acute insulin
response by sodium salicylate. A glucose dose-related phenomenon.
Diabetes, 27(7), pp. 750–756.
Chothia, M.-Y. et al. 2014. Bolus Administration of Intravenous Glucose in
the Treatment of Hyperkalemia: A Randomized Controlled Trial.
Nephron Physiology. 126(1), pp. 1–8.
Couser, W. G. et al. 2011. The contribution of chronic kidney disease to the
global burden of major noncommunicable diseases. Kidney
International. Elsevier Inc, 80(12), pp. 1258–1270.
Denic, A., Glassock, R. J. and Rule, A. D. 2016. Structural and Functional
Changes With the Aging Kidney. Advances in Chronic Kidney
Disease. Elsevier Ltd, 23(1), pp. 19–28.
Dipiro, C. V. Ed. 2015. Electrolyte Homeostasis. In: Wells, B. G. et al.
(Eds.). Pharmacotherapy Handbook. 9th edn. New York: McGraw-
Hill Education, p. 808.
Ebert, N. et al. 2017. Prevalence of reduced kidney function and
albuminuria in older adults: The Berlin initiative study. Nephrology
Dialysis Transplantation, 32(6), pp. 997–1005.
El-Solh, A. A., Jaoude, P. A. and Porhomayon, J. 2010. Bicarbonate therapy
in the treatment of septic shock: A second look. Internal and
Emergency Medicine, 5(4), pp. 341–347.
Espinel, E. et al. 2013. Risk of hyperkalemia in patients with moderate
chronic kidney disease initiating angiotensin converting enzyme
inhibitors or angiotensin receptor blockers: A randomized study.
BMC Research Notes, 6(1), pp. 1–9.
Faselis, C. Ed. 2016. USMLE: STEP 2 CK Lecture Note Internal
Medicine 2017. New York: Kaplan Medical, pp. 285–286.
FDA. 2010. Kayexalate (sodium polystyrene sulfonate) powder label -
FDA.Diakses:www.accessdata.fda.gov/drugsatfda_docs/label/2011/0
11287s023lbl.pdf, pada tanggal 20 November 2018.

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
81

Fleet, J. L. et al. 2012. Validity of the International Classification of

Diseases 10th revision code for hyperkalaemia in elderly patients at
presentation to an emergency department and at hospital admission.
BMJ Open, 2(6), pp. 1–9.
Guyton, Arthur C., and Hall, John E. 2016. Buku Ajar Fisiologi
Kedokteran. Diterjemahkan oleh Siagian, M. Singapore:Elsevier, p.
104; 356–357.
Gravatt, L. A. H., Donohoe, K. L. and DiPiro, C. V. 2017. Nausea and
Vomiting. In: Dipiro, J. T. et al. (eds) Pharmacotheraphy: A
Pathophysiologic Approach. 10th edn. New York: McGraw-Hill
Education, p. 1596.
Hardjono, S. dan Widiandani, T. 2016. Hubungan Struktur-Aktivitas
Senyawa Diuretika’, In: Siswandono (Ed.). Kimia Medisinal. 2nd
edn. Surabaya: Airlangga University Press, p. 261.
Harel, Z. and Kamel, K. S. 2016. Optimal Dose and Method of
Administration of Intravenous Insulin in the Management of
Emergency Hyperkalemia: A Systematic Review. PloS one, 11(5), p.
1-8.
Hector Debra ,Rangan Anna, Louie Jimmy, Flood Vicki, G. T. 2009). Soft
drinks, weight status and health: a review. Sydney.
Hill, N. R. et al. 2016. Global Prevalence of Chronic Kidney Disease – A
Systematic Review and Meta-Analysis. PLOS ONE, 11(7), pp. 1–
18.
Hoek, T. L. V. C. et al. 2010. Part 12: Cardiac Arrest in Special Situations:
American Heart Association Guidelines for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care. Circulation,
122(3), pp. S829–S861.
Jackson, E. K. 2018. Drugs Affecting Renal Excretory Function. In:
Brunton, L. L., Dandan, R. H., and Knollmann, B. C. (Eds.).
Goodman & Gilman’s The Pharmacological Basis of Theurapetics.
13th edn. New York: McGraw-Hill Education, p. 455.
Kementrian Kesehatan Republik Indonesia
(KEMENKES).2014.Farmakope Indonesia Edisi V.Jakarta:
Kementrian Kesehatan Republik Indonesia, p.305.
Kementrian Kesehatan (KEMENKES) .2017. Data dan Informasi Profil
Kesehatan Indonesia.

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
82

Kennedy, M. S. N. and Masharani, U. 2015. Pancreatic Hormones &

Antidiabetic Drugs. In: Katzung, B. G. and Trevor, A. J. (Eds.).
Basic & Clinical Pharmacology. 13th edn. New York, p. 724; 727-
729.
Khosla, N. 2017. Common Clinical Problems During Hemodialysis. In:
Nissenson, A. R. and Fine, R. N. (Eds.). Handbook of Dialysis
Therapy. 5th edn. Philadelphia: Elsevier, pp. 317–323.
Komers, R., Meyer, T. W. and Anderson, S. 2013. Pathophysiology and
Nephron Adaptation in Chronic Kidney Disease. In: Coffman, T. M.
et al. (Eds.). Schrier’s Diseases Of The Kidney. 9th edn.
Philadelphia: Wolters Kluwers, pp. 2214–2216
Kutlugun et al. 2017. Frequency of Hyperkalemia in Chronıc Kidney
Patients Under Regular Nephrology Care. Journal of Clinical
Nephrology and Renal Care, 3(2), pp. 1–5.
Lexicomp. Ed. 2014. Drug Information Handbook. 23rd edn. Ohio:
Wolters Kluwers, p. 946; 1106; 1948.
Liamis, G. 2014. Diabetes mellitus and electrolyte disorders. World
Journal of Clinical Cases, 2(10), p. 488.
Mandal, A. K. 2014. Hyperkalemia: Pathophysiology, Diagnosis,
Treatment, and Prevention. In: Mandal, A. K. and Prakash, J. (Eds).
Textbook of Nephrology. 3rd edn. New Delhi: Jaypee Brothers
Medical Publishers (P) Ltd, p. 64.
McEvoy, G. K. Ed. 2011. AHFS Drug Information Essentials. Maryland:
American Society of Health-System Pharmacists, Inc.
McEvoy, G. K. Ed. 2017. Handbook of Injectable Drugs. 19th edn.
Wisconsin: American Society of Health-System Pharmacist, Inc.,
p.707-713.
Mistry, M. et al. 2016. Evaluation of Sodium Polystyrene Sulfonate Dosing
Strategies in the Inpatient Management of Hyperkalemia. Annals of
Pharmacotherapy, 50(6), pp. 455–462.

Mount, D. 2015. Fluid and Electrolyte Disturbances. In: Kasper, D. et al.

(Eds.). Harrison’s Principles of Internal Medicine. 19th edn. New
York: McGraw-Hill Education, p. 312.
Musyahida, R.A. 2016. Studi Penggunaan Terapi Furosemid pada Pasien
Penyakit Ginjal Kronik (PGK) Stadium V di Rumkital Dr. Ramelan

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
83

Surabaya.Skripsi.Universitas Airlangga.Surabaya, p. 86.

Nahas, M. E. 2003. Progression in Chronic Renal Failure. In: Johnson, R.
and Feehally, J. (eds) Comprehensive Clinical Nephrology. 2nd edn.
Toronto: Mosby Inc, p. 845.
Neal, M. J. 2016. Medical Pharmacology at a Glance. 8th edn. West
Sussex: John Wiley & Sons, Ltd, p.29.
Neuen, B. L. et al. 2017. Chronic kidney disease and the global NCDs
agenda. BMJ Global Health, 2(2), pp. 1–4.
Nilsson, E. et al. 2017. Incidence and determinants of hyperkalemia and
hypokalemia in a large healthcare system. International Journal of
Cardiology. The Authors, 245, pp. 277–284.
Nourizadeh, M. et al. 2016. Study the Effect of High Dialysate Potassium
Solution in Comparison to Low Potassium Dialysate Solution in End
Stage Renal Disease Patients. Health, 8, pp. 363–369.
Oh, S. W. and Han, S. Y. 2015. Loop diuretics in clinical practice.
Electrolyte and Blood Pressure, 13(1), pp. 17–21.
Ookuma, T. et al. 2015. The clinical relevance of plasma potassium
abnormalities on admission in trauma patients: a retrospective
observational study. Journal of Intensive Care, 3(37), pp. 1–7.
Palmer, B. F. 2014. Regulation Of Potassium Homeostasis. Clinical
Journal of the American Society of Nephrology, 10(6), pp. 1050–
1060.
Palmer, B. F. and Clegg, D. J. 2016. Physiology and pathophysiology of
potassium homeostasis. Advances in Physiology Education, 40(4),
pp. 480–490.
Palmer, B. F. and Jr, T. D. D. 2018. Disorders of Potassium Metabolism. In:
Schrier, R. W. (Ed.). Renal and Electrolyte Disorders. 8th edn.
Philadelphia: Wolters Kluwers, p. 305; 314.
Perazella, M. A. and Rastegar, A. 2013. Disorders of Potassium and Acid-
Base Metabolism in Association with Renal Disease. In: Coffman, T.
M. et al. (Eds.). Schrier’s Diseases Of The Kidney. 9th edn.
Philadelphia: Lippincott Williams & Wilkins, p. 2082.
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2015.
Pedoman Tatalaksana Gagal Jantung. Buku Pedoman Tatalaksana
Gagal Jantung, pp. 14–27.

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
84

Pharmaceutical Care Network Europe Foundation (PCNE) .2017.

Classification for Drug Related Problems. V8.02, p.3.
Pun, P. H. et al. 2017. Serum Potassium Levels and Risk of Sudden Cardiac
Death Among Patients With Chronic Kidney Disease and Significant
Coronary Artery Disease. Kidney International Reports. Elsevier
Inc, 2(6), pp. 1122–1131.
Raebel, M. A. 2012. Hyperkalemia Associated with Use of Angiotensin-
Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Cardiovascular Therapeutics, 30(3), pp. 156–166.
Riset Kesehatan Dasar (RISKESDAS).2018. Hasil RISKESDAS 2018.
Diakses:http://www.depkes.go.id/resources/download/infoterkini/ma
teri_rakorpop_2018/Hasil Riskesdas 2018.pdf, pada tanggal 25
Januari 2019.
Royal Pharmaceutical Society (RPS).2018. British National Formulary.
76th edn. London: Pharmaceutical Press, p. 1014.
Sam, R., Pearce, D. and Ives, H. E. 2015. Diuretic Agents. In: Katzung, B.
G. and Trevor, A. J. (Eds.). Basic & Clinical Pharmacology. 13th
edn. New York: McGraw-Hill Education, p. 257.
Sarwar, C. M. S. et al. 2016.Hyperkalemia in Heart Failure. Journal of the
American College of Cardiology, 68(14), pp. 1575–1589.
Saseen, J. J. and MacLaughlin, E. J. 2016.Hypertension. In: Dipiro, J. T. et
al. (Eds.). Pharmacotheraphy: A Pathophysiologic Approach. 10th
edn. New York: McGraw-Hill Education, pp. 497–566.
Saxena, A. and Meshram, S. V. 2018. Predictors of Mortality in Acute
Kidney Injury Patients Admitted to Medicine Intensive Care Unit in
a Rural Tertiary Care Hospital’, Indian Journal of Critical Care
Medicine, 22(4), pp. 231–237.
Schonder, K. S. 2016. Chronic and End-Stage Renal Disease. In: Chisholm-
Burns, M. A. et al. (Eds.). Pharmacotherapy Principles & Practice.
4th edn. New York: McGraw-Hill Education, p. 422.
Sharma, S. et al. 2007. Severe hyperkalemia with normal
electrocardiogram’, Indian Journal of Critical Care Medicine,
11(4), p. 215.
Sowinski, K. M. et al. 2005. Subcutaneous Terbutaline Use in CKD to
Reduce Potassium Concentrations. American Journal of Kidney
Diseases, 45(6), pp. 1040–1045.

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI

 I R - PERPUSTAKAAN UNIVERSITAS AIRLANGGA
85

Sweetman, S. C. Ed. 2009. Martindale:The Complete Drug Reference.

36th edn. London: Pharmaceutical Press, p. 449; 1671-1674; 946.
Tatro, D. S. Ed. .2009. Drug Interaction Facts 2009: The Authority On
Drug Interaction. London:Wolters Kluwers.
Thomsen, R. W. et al. 2018. Elevated potassium levels in patients with
chronic kidney disease: occurrence, risk factors and clinical
outcomes— a Danish population-based cohort study. Nephrology
Dialysis Transplantation, 33(9), p.1610-1620.
Trefz, F., Constable, P. and Lorenz, I. 2017. Effect of Intravenous Small-
Volume Hypertonic Sodium Bicarbonate, Sodium Chloride, and
Glucose in Decreasing Plasma Potassium Concentration in
Hyperkalemic Neonatal Calves with Diarrhea. Journal of Vetenary
Internal Medicine, 31(3), pp. 907–921.
Thruhlar, A. et al. 2015. European Resucitation Council Guidelines for
Resucitation 2015: Section 4.Cardiac Arrest in Special
Circumstances. Resucitation, 95, pp. 148–201.
Weinstein, J. R. and Anderson, S. 2010. The Aging Kidney: Physiological
Changes. Advances in Chronic Kidney Disease, 17(4), pp. 302–307.
World Health Organization (WHO). 2003. Introduction to Drug Utilization
Research. Geneva: WHO, p.8.

SKRIPSI STUDI PENGGUNAAN TERAPI... RIFDAH ATIKAH SAFITRI